1. Home
  2. HLSQ vs VRAX Comparison

HLSQ vs VRAX Comparison

Compare HLSQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tessera Defense and Homeland Security Inc. Common Stock

HLSQ

Tessera Defense and Homeland Security Inc. Common Stock

N/A

Current Price

$0.16

Market Cap

972.0K

Sector

Health Care

ML Signal

N/A

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$1.17

Market Cap

972.3K

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HLSQ
VRAX
Founded
2015
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
972.0K
972.3K
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
HLSQ
VRAX
Price
$0.16
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 292.0K
152.5K
Earning Date
11-16-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 560.42
N/A
EPS
★ 3.56
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.04
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.10
52 Week High
$7.70
$13.19

Technical Indicators

Market Signals
Indicator
HLSQ
VRAX
Relative Strength Index (RSI) 9.04 27.04
Support Level N/A $0.15
Resistance Level $2.85 $2.92
Average True Range (ATR) 0.32 0.14
MACD -0.00 0.01
Stochastic Oscillator 0.63 7.46

Price Performance

Historical Comparison
HLSQ
VRAX

About HLSQ Tessera Defense and Homeland Security Inc. Common Stock

Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: